| Code |
Title |
|
–
|
Top Categories
|
|
X |
New Technology
|
|
XW |
Anatomical Regions
|
|
XW0
|
Introduction
New Technology, Anatomical Regions, Introduction
|
|
XW0D |
Mouth and Pharynx
|
|
XW0DX |
External
|
|
XW0DX6 |
Lefamulin Anti-infective
|
|
XW0DX66
|
New Technology Group 6
Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6
|
|
XW0DX8 |
Uridine Triacetate
|
|
XW0DX82
|
New Technology Group 2
Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2
|
|
XW0DXF |
Other New Technology Therapeutic Substance
|
|
XW0DXF5
|
New Technology Group 5
Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5
|
|
XW0DXJ |
Apalutamide Antineoplastic
|
|
XW0DXJ5
|
New Technology Group 5
Introduction of Apalutamide Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
|
|
XW0DXL |
Erdafitinib Antineoplastic
|
|
XW0DXL5
|
New Technology Group 5
Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
|
|
XW0DXM |
Baricitinib
|
|
XW0DXM6
|
New Technology Group 6
Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6
|
|
XW0DXR |
Venetoclax Antineoplastic
|
|
XW0DXR5
|
New Technology Group 5
Introduction of Venetoclax Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
|
|
XW0DXT |
Ruxolitinib
|
|
XW0DXT5
|
New Technology Group 5
Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5
|
|
XW0DXV |
Gilteritinib Antineoplastic
|
|
XW0DXV5
|
New Technology Group 5
Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5
|